Harbour BioMed-B (02142): Batoclimab Injection (subcutaneous injection) approved by NMPA for marketing for the treatment of generalized myasthenia gravis

Zhitong Finance APP News, HBM Holdings-B (02142) announced that the National Medical Products Administration (NMPA) of China has approved the marketing of batoclimab injection (subcutaneous injection) (batoclimab subcutaneous injection) (170 mg (1 mL)/vial) for use in combination with conventional therapeutic drugs for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). Batoclimab (HBM9161) is the company's core product under Chapter 18A of the Listing Rules. Batoclimab subcutaneous injection is the Group's first approved product and also the first anti-neonatal Fc receptor (FcRn) therapy to complete full clinical development for gMG patients in China.